Vor Biopharma Inc. (VOR)
NMS · Healthcare · Biotechnology
$13.29
+0.99%
Closing price as of 2026-06-08 · Source: TEK2day Finance
Key Metrics
Market Cap
$830.1M
Exchange
NMS
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -274.3M | -28.1M | -36.0M | -35.2M |
| Net Income | -1.6B | -812.7M | 1.7B | -219.6M |
| Diluted EPS | $-251.20 | $-121.63 | $nan | $-5.11 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -93.4M | -126.0M | -121.2M | -371.6M |
| Net Income | -92.1M | -117.9M | -116.9M | -696.0M |
| Diluted EPS | $-46.60 | $-35.00 | $-34.03 | $-70.50 |